Paxman are excited to share our shortlisting for an award at the Medilink North of England Healthcare Business Awards 2025!
The Medilink HealthCare Business Awards celebrates outstanding innovations and successes in medical technology, recognising the achievements of sector companies in the North.
This showcase highlights the North’s exceptional capabilities, innovation, and expertise in the life sciences industry. The 2025 awards evening will be held on Thursday the 8th of May at 8pm at the Lowry Hotel in Manchester.
Paxman has had a long-standing collaborative relationship with Dr Nik Georgopoulos, an Associate Professor at Sheffield Hallam University. Building on his expertise in epithelial cell biology, his research has enabled the generation of biological evidence which supports the ability of scalp cooling to protect from chemotherapy induced hair loss. The exchange of knowledge between Paxman and Dr. Georgopoulos has supported ambitious, biology driven research and development strategies, and contributed to our status as the world leader in cryotherapy for chemotherapy side effect management.
As more and more patients are being treated with chemotherapy, increasing numbers are suffering from severe and highly traumatic side effects. Over the years, cancer treatment has evolved from being singularly focussed on curing cancer, to acknowledging that the side effects of treatment, both psychological and physical, can be equally traumatic.
While scalp cooling is highly effective for most patients in enabling them to keep their hair, it does not work for every individual. Our partnership has developed novel approaches for the advancement of the effectiveness of scalp cooling. More recently, the partnership has been supporting research that aims to inform the design of limb cooling devices currently under development.
While Paxman is a world leader in cooling based medical devices, scalp cooling is still not a perfect process. There are still variations in results, even for those patients with the same hair type and chemotherapy drug regimen.
Paxman’s work with Dr. Nik Georgopoulos at Sheffield Hallam University has yielded positive evidence that a topical formulation could suppress or prevent toxicity to hair follicles under conditions when cooling may not adequately protect. The aim is to be able to formulate an agent in such a way that it can be applied topically to the scalp just before drug infusion. The formulation will promote the efficient delivery of the antioxidant to the follicle’s rapidly dividing cells to protect from chemotherapy-mediated toxicity.
Research and development are increasingly important for Paxman, as we remain committed to improving the efficacy of scalp cooling for patients around the world. We recognise that constant innovation provides huge potential, not only for our technology as it stands now, but also the immense opportunities that pushing the boundaries of cryotherapy provides for the future. The capabilities and improvements being unlocked by the partnership with Sheffield Hallam University can ensure that we continually improve outcomes for patients.
Wish us luck as we find out the results on the 8th May. If you’d like to come and celebrate with us, tickets are available for the event on the Medilink North of England website: medilink.co.uk/awards
